Search research articles
Contact Us
Filters
Showing results (101-110 of 131) with videos related to
Page
of 14
Sort By:
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Blood
|
June 20, 2015
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma
Luca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Hemasphere
|
December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma
Graham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Blood Advances
|
May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Anastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, et al.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 131) with videos related to
Sort By:
Page
of 14
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Blood
|
June 20, 2015
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma
Luca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Hemasphere
|
December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma
Graham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Blood Advances
|
May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Anastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, et al.
Molecular Cancer Therapeutics
|
December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Biorxiv : the Preprint Server for Biology
|
January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Page
of 14